Compare STEL & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STEL | FTRE |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | STEL | FTRE |
|---|---|---|
| Price | $30.73 | $16.75 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 8 |
| Target Price | ★ $31.33 | $12.64 |
| AVG Volume (30 Days) | 266.7K | ★ 1.4M |
| Earning Date | 01-29-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.94 | N/A |
| Revenue | $416,539,000.00 | ★ $2,759,900,000.00 |
| Revenue This Year | N/A | $3.17 |
| Revenue Next Year | $3.41 | $0.11 |
| P/E Ratio | $15.86 | ★ N/A |
| Revenue Growth | N/A | ★ 1.88 |
| 52 Week Low | $24.13 | $3.97 |
| 52 Week High | $32.74 | $20.26 |
| Indicator | STEL | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 41.30 | 63.79 |
| Support Level | $31.16 | $17.06 |
| Resistance Level | $31.14 | $17.69 |
| Average True Range (ATR) | 0.60 | 0.81 |
| MACD | -0.19 | -0.14 |
| Stochastic Oscillator | 10.80 | 49.13 |
Stellar Bancorp Inc is a U.S. based bank holding company. Through its subsidiary, Stellar Bank, the company provides a diversified range of commercial banking services predominantly to small to medium sized businesses, professionals, and individual customers. Its offerings include different types of loans, such as mortgage loans, home equity loans, automobile loans, etc.; deposit products, such as checking accounts, commercial accounts, money market accounts, savings accounts, etc.; and other banking services like mobile banking, debit cards, cash management and wire transfer services, letters of credit, and others.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.